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iscussion
r Steven W. Guyton (Seattle, Wash). Thank you, Dr Gavra, for
n excellent presentation and for the opportunity to review your
anuscript before the meeting.
Active endocarditis that cannot be managed with antibiotic
herapy alone is a devastating problem, as you have so well
llustrated. You might illustrate this as well by including a graph
ndicating the freedom from mortality and morbidity—reoperation,
ecurrent endocarditis, thromboembolism, stroke, heart block, re-
al failure, sternal infection, and others. I anticipate that close to
00% of your patients will show complications during your 10- to
5-year follow-up. I agree with your emphasis on aggressive
ébridement of all infected tissue and less emphasis on the type of
rosthesis. The prostheses you used were approximately 2:1 me-
hanical versus bioprosthetic and then some homografts. Have you
een a difference in outcomes depending on your choice of pros-
hesis, and what is your preference at present?
The Journal of ThoracicDr Gavra. I am not the senior surgeon, but I can assure you
hat Dr David’s approach is to excise all infected tissues to
llow implantation of a prosthetic valve in healthy and strong
issues. He believes that the outcomes for patients with para-
alvular abscess is influenced more by the surgeon’s ability to
ecognize and extirpate all infected tissue than by the type of
rosthetic valve implanted.
Dr Guyton. Did you look at the outcomes, though, related to
he type of prosthesis that was used as to whether your data
howed any difference?
Dr Gavra. No.
Dr Guyton. Recurrent endocarditis treated medically had a
ismal prognosis, with a 75% mortality reported in the manuscript.
omografts have been touted as more resistant to recurrent infec-
ion. Is this an argument for the use of homografts?
Dr Gavra. With respect to the patients who had recurrent
ndocarditis, I’d have to say that the 22 patients who were treated
ith antibiotics only were treated elsewhere, not in Toronto Gen-
ral Hospital and they didn’t benefit from surgery. I would suppose
his to be one of the reasons that mortality is so high for this
ubgroup of endocarditis.
Dr Guyton. Thank you for that clarification. Ten percent of
our patients were operated on for large vegetations. This is the
rst time I have seen this as an indication for surgery from your
roup. Why were operations performed for vegetation size? I know
y cardiologists get skittish about these vegetations, but I’ve not
een convinced that operating for the size of vegetations is appro-
riate.
Dr Gavra. Because of fear of embolization, vegetations larger
han 10 mm in diameter were considered an indication for surgery.
Dr Guyton. I think we might want to be very careful about
sing that as an indication for surgery. In the medical literature,
here is encouragement for shorter durations of antibiotic treat-
ent, which I have found disturbing in this population of patients
iven the consequences of treatment failure. I note that you re-
orted freedom from recurrent endocarditis to be better after
rosthetic valve endocarditis. Were these patients treated differ-
ntly because they already had prosthetic valves, and what is your
tandard course of antibiotic therapy?
Dr Gavra. The patients in this study received intravenous
ntibiotics for a total of 6 weeks. Although my slide showed a
ower risk of recurrent endocarditis among patients with prosthetic
alve than in those with native valve endocarditis, the difference
as not statistically significant.
Dr Guyton. In S aureus infection timing of operation is im-
ortant. As a tertiary referral center, you did not always have
ontrol over when the operation occurred relative to the date of
resentation. In analyzing the data, did you find a difference in
utcomes depending on when the patient was operated on versus
he time of presentation?
Dr Gavra. Although the overall mortality among patients with
aureus endocarditis was higher than that among those with other
acteria, I don’t know whether timing of surgery played a role in
he outcome.
Dr Guyton. Having that analysis might help us evaluate the
ata a little bit more extensively. Thank you for opportunity to
eview the manuscript and to discuss this presentation.Dr Gavra. Thank you very much, Dr Guyton.
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